Contineum Therapeutics (CTNM) Net Margin (2023)

Contineum Therapeutics (CTNM) posted quarterly Net Margin of 83.14% for Q2 2023.

Contineum Therapeutics (CTNM) Net Margin (2023) Analysis & Trends

Contineum Therapeutics' Net Margin history runs 1 years deep, the most recent figure standing at 83.14% for Q2 2023.

In Q2 2023, Net Margin changed N/A year-over-year to 83.14%; the TTM figure through Jun 2024 stood at 71.76% (changed N/A YoY), while the FY2023 annual figure was 36.57%, changed N/A from the prior year.
Net Margin for Q2 2023 stood at 83.14%.
The five-year high for Net Margin was 83.14% in Q2 2023, with the low at 83.14% in Q2 2023.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Margin (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	32.99%
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	30.23%
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	30.33%
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	13.90%
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	30.98%
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	12.09%
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	12.74%
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-3.12%
10	Contineum Therapeutics	533.73 Mn	533.73 Mn	-	-

Historic Data

Download Data

Date	Value
Jun 30, 2023	83.14%